A. A. Sadiq Et Al. , "VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom) plus zimberelimab (zim) plus chemotherapy (chemo) or zim plus chemo followed by adjuvant dom plus zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC)," Special Clinical Science Symposia , ELECTR NETWORK, 2024
Sadiq, A. A. Et Al. 2024. VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom) plus zimberelimab (zim) plus chemotherapy (chemo) or zim plus chemo followed by adjuvant dom plus zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC). Special Clinical Science Symposia , (ELECTR NETWORK).
Sadiq, A. A., Shamai, S., Lin, S., Han, J., Baijal, S., Yazici, O., ... Barrios, C. H.(2024). VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom) plus zimberelimab (zim) plus chemotherapy (chemo) or zim plus chemo followed by adjuvant dom plus zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC) . Special Clinical Science Symposia, ELECTR NETWORK
Sadiq, Ahad Et Al. "VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom) plus zimberelimab (zim) plus chemotherapy (chemo) or zim plus chemo followed by adjuvant dom plus zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC)," Special Clinical Science Symposia, ELECTR NETWORK, 2024
Sadiq, Ahad A. Et Al. "VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom) plus zimberelimab (zim) plus chemotherapy (chemo) or zim plus chemo followed by adjuvant dom plus zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC)." Special Clinical Science Symposia , ELECTR NETWORK, 2024
Sadiq, A. A. Et Al. (2024) . "VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom) plus zimberelimab (zim) plus chemotherapy (chemo) or zim plus chemo followed by adjuvant dom plus zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC)." Special Clinical Science Symposia , ELECTR NETWORK.
@conferencepaper{conferencepaper, author={Ahad Ali Sadiq Et Al. }, title={VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom) plus zimberelimab (zim) plus chemotherapy (chemo) or zim plus chemo followed by adjuvant dom plus zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC)}, congress name={Special Clinical Science Symposia}, city={}, country={ELECTR NETWORK}, year={2024}}